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Background: Evidence has been accumulating that it may be possible to achieve prevention in psychotic
disorders. The aim of the Prevention Of Psychosis (POP) study is to reduce the annual incidence of psychotic
disorders in a catchment area population through detection and intervention in the prodromal phase of disorder.
Prodromal patients will be recruited through information campaigns modelled on the Scandinavian early Treatment
and Intervention in Psychosis (TIPS) study and assessed by low-threshold detection teams.
Methods/Design: The study will use a parallel control design comparing the incidence of first episode psychotic
disorders between two Norwegian catchment areas with prodromal detection and treatment (Stavanger and
Fonna) with two catchment areas without a prodromal intervention program (Bergen and Østfold). The primary aim
of the current study is to test the effect of a Prodromal Detection and Treatment program at the health care
systems level. The study will investigate: 1) If the combination of information campaigns and detection teams
modelled will help in identifying individuals (age 13–65, fulfilling study inclusion criteria) at high risk of developing
psychosis early, and 2) If a graded, multi-modal treatment program will reduce rates of conversion compared to the
rates seen in follow-along assessments.
Discussion: Positive results could potentially revolutionize therapy by treating risk earlier rather than disorder later
and could open a new era of early detection and intervention in psychosis. Negative results will suggest that the
potential for psychosis is determined early in life and that research should focus more on genetically linked
neurodevelopmental processes.
If we can identify people about to become psychotic with high accuracy, we can track them to understand more
about how psychosis unfolds. Appropriate intervention at this stage could also prevent or delay the onset of
psychosis and/or subsequent deterioration, i.e., social and instrumental disability, suicide, aggressive behavior,
affective- and cognitive deficits.
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Mental illness is the largest cause of disability in devel-
oped countries, and psychotic disorders (schizophrenia/
bipolar disorder) are ranked among the leading causes of
total burden of disease and cost of lifetime disability
worldwide. In spite of high research activity the mecha-
nisms behind these disorders are still primarily unknown
and the effects of available treatments are also limited
and mostly palliative.
Most patients experience a relative long period with
non-psychotic symptoms before their first psychotic epi-
sode characterized by unspecific- and more specific symp-
tom constellations (prodrome/Ultra High Risk (UHR)
state). At the onset of psychosis, many have already expe-
rienced a loss of cognitive- and psychosocial functioning.
We now know that individuals at high risk for psychotic
disorders can be identified before this point of time. The
present study builds on experiences from the Scandinavian
Early Treatment and Intervention in Psychosis (TIPS)
study [1,2], where the use of information campaigns and
detection teams were instrumental in reducing the dur-
ation of untreated psychotic symptoms in the first episode.
This reduction was followed by a more benign course of
the disorder over ten years of treatment [3]. We here
hypothesize that a similar program (Prodromal Detection
and Treatment program - PDT) - aimed at identifying and
treating help seeking individuals at high risk for developing
psychotic disorders will a) significantly increase the num-
ber of high risk individuals that get in contact with the
relevant services and b) that these individuals will be de-
tected at a very early stage of illness development. After
contact the high risk individuals will be allocated to a
structured follow-along by a designated case manager
or to a graded, multi-modal and primarily psychosocial
treatment intervention. Patients will be offered active
antipsychotic medication only at imminent risk of con-
version to psychosis. We also hypothesize that the
multi-modal treatment intervention will significantly
reduce the number of persons converting to psychosis,
and thus influence the incidence of new cases of first-
episode psychosis. The study is designed as a regional
multi-center study, involving central research- and
clinical psychiatric organizations across the Health
Vest region in Southern Norway, with significant inter-
national cooperation, and will involve all service levels
from general practitioners to specialized psychiatric
services. Two Norwegian treatment centers covering a
population of 440 000 will collaborate in recruiting
prodromal patients to the study: Stavanger and Fonna
hospitals. The project organization has additional in-
volvement from the research departments at Bergen
University Hospitals and Sykehuset Østfold Hospital
for establishing a first-episode psychosis incidence
registration as another part of this research initiative.All study enrolled patients will be asked for blood samples
and to be a part of the Norwegian NASATS program –
Severe Mental Illness, aiming to identify new genetic
variants associated with severe mental disorders [4].
Rationale
Schizophrenia and other psychotic disorders are serious,
costly, and disabling. They typically emerge in late adoles-
cence and early adulthood, a critical phase of neurological,
psychological and social development. Even if the number
of new cases per year is low (varying between 15 in the
TIPS study [1] to −30 per 100 000 per year [5], their early
onsets combined with a high risk of chronic symptoms
makes these into disorders with a high prevalence (1%).
Many patients display significant impairments already
at start of first treatment, and it is known that course
and outcome are poorer in patients that come late into
treatment. Results from the TIPS study show for the first
time that treatment can be initiated significantly earlier
in psychotic disorders. This is in turn associated with
less severe psychotic symptoms, suicidality and func-
tional disabilities already at first treatment [1,6]. Follow-
up after two- and five years in treatment demonstrate
long-term advantages in the form of less severe negative
symptoms, cognitive deficits, depressive symptoms and
global dysfunction [7,8] and for the level of recovery rates
up to ten year follow up. Early detection and treatment
thus appears to have reduced collateral damage in first
psychosis and altered the course and prognosis of the dis-
order (i.e. achieved secondary prevention). Given these
empirical data it is timely to test whether very early inter-
vention can actually prevent the development of disorder
in individuals at high risk (i.e. primary prevention).
The symptomatic “ultra-high-risk” (UHR) or “pro-
dromal” state has been a part of schizophrenia. In the past
decade it has also become a reliably identifiable clinical
constellation, with clear power to predict the onset of
psychotic disorder (schizophrenia and other psychotic dis-
orders) within the near future. The field of UHR research
has the potential to shed light on the development of
major psychotic disorders and to alter their course. It also
provides a rationale for service provision to those in need
of help who could not previously access it and the possi-
bility of changing trajectories for those with vulnerability
to psychotic illnesses [9]. These UHR individuals exhibit
one or more of the existing prodromal syndromes: The at-
tenuated positive symptom (APS) syndrome and/or the
genetic risk and deterioration (GRD) syndrome. The most
commonly used instruments to assess prodromal states
include those developed in Melbourne (Comprehensive
Assessment of At-Risk Mental States (CAARMS)) [10]
and New Haven (Structured Interview for Prodromal Syn-
dromes (SIPS) [11]. Because the prodrome is clinical in
nature, persons developing these symptoms often seek a
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school counselor or a friend in a healthcare position. Be-
cause the UHR state is a relatively rare and new clinical
constellation not widely known, recruiting symptomatic,
help-seeking persons at risk for psychosis requires active
outreach to healthcare-oriented referral sources [12]. This
includes educating referral sources about the prodrome,
training and maintaining triage staff and conducting rapid,
low threshold evaluations of referrals.
Conversion to psychosis in prodromal samples
In studies using the New Haven/Melbourne UHR cri-
teria, preliminary reports found a 40-50% annual rate of
conversion to psychosis of identified individuals [13,14].
This is in line with studies using similar criteria, includ-
ing studies from Cologne who found a conversion rate
of 49 % after 9.6 years [15] and a London based study
finding conversion rates of 50% after 2 years [16]. A later
study from Melbourne found conversion rates of 34.6%
in a sample of 104 UHR subjects identified with the
CAARMS [17]. The more recent North American Pro-
dromal Longitudinal Study (NAPLS) - found that 28% of
the cases in the study converted to during follow-up.
The rate of conversion showed a decelerating trend dur-
ing the follow-up, with the majority of converters the
first two years of the study [18]. At 2.5 year follow up a
conversion rate of 29% is reported [19]. In the NAPLS
sample, several variables predicted conversion; the most
powerful were a diagnosis of schizotypal personality
disorder, substance abuse, a recent decline in function-
ing, unusual thought content and/or suspicion. Recent
reports from the prodromal clinic in Melbourne docu-
ment a falling trend for conversion rates to psychosis
among consecutive annual samples between1995-2005
[20]. This declining rate was correlated with a decrease
in the duration of prodromal symptoms prior to clinic
intake evaluation. Changes in referral sources may also
have increased the rate of “false positive” prodromal sub-
jects, i.e. persons who would not subsequently convert
to psychosis anyhow. In a recent study by Yung et al.,
[21] the psychosis conversion rate at 6 month follow-up
is 7%. In a recent review article by Simon et al. [22] of
31 studies the reported transition rates varied from 7 to
54% (mean rate = 24%). Follow-up periods ranged from 6
to approximately 40 months. In a meta-study by Fusar-
Poli et al. [9] of 2502 patients there was a consistent tran-
sition risk, of 18% after 6 months of follow-up, 22% after 1
year, 29% after 2 years, and 36% after 3 years.
Controlled clinical trials of treatment in the prodrome
In a recent meta-analysis by Stafford et al. [23] 11 in-
cluded RCT studies made eight comparisons. The authors
identified four trials comparing CBT with supportive
counseling and monitoring [24-27]. Two trials comparedrisperidone and CBT with supportive counseling [28,29].
Further on; one study each compared risperidone and
CBT with placebo and CBT [28], olanzapine with placebo
[30], integrated therapies with supportive counselling [31]
integrated therapies with standard treatment [32] Omega-3
fatty acids with placebo [33] and amisulpride plus a needs
based intervention with the needs based intervention alone
[34]. All these studies measured conversion to psychosis as
the primary dependent variable. The studies demonstrate
that treatment (psychosocial, pharmacotherapeutic or both)
reduce the conversion rate to psychosis. The McGlashan
study demonstrated a significant effect in reducing the se-
verity of positive prodromal symptoms, but also major
negative side effects in the form of weight gain. Further,
there are preliminary reports indicating a possible effect on
conversion rates from psychoeducational family work [35].
These recent studies have contributed to the availability for
larger datasets, which suggests that transition to psychosis
from a high risk mental state could be preventable. Overall,
in the meta-analysis by Stafford et al. [23] the five trials of
CBT had a moderate effect on transition to psychosis at
both 12 and 18 months. In the sensitivity analyses the effect
of CBT on transition remained significant at 12 months.
There has also been evidence that complex psychosocial in-
terventions could reduce transition or delay onset of psych-
osis, relative to supportive counseling or treatment as
usual. For the study of Omega-3 fatty acids [33] low quality
evidence suggests a beneficial effect for a 12 week course of
nutritional supplementation compared with placebo.
Neurocognitive and structural brain imaging studies in
prodromal samples
Neuroimaging and neurocognitive studies have attempted
to find reliable psychosis high-risk biomarkers. Two re-
cent meta-analyses at high risk for psychosis showed that
high-risk subjects are already neurocognitively impaired
relative to matched controls [36,37]. There was a high
variability across individual studies, and no reliable neuro-
cognitive biomarkers have adequate sensitivity and specifi-
city for clinical application in individual cases. Across
neurocognitive domains, such as executive function, verbal
fluency, attention, visual and verbal memory, and working
memory, effect sizes were small to medium. Available re-
search confirms that psychosis high risk is characterized by
widespread mild cognitive deficits at a level that is inter-
mediate between healthy individuals and those diagnosed
with schizophrenia [38] and comparable to those at familial
risk [39]. Neurocognitive impairments in psychosis high
risk predict longitudinal functioning [40]. The magnitude
of neurocognitive deficits is greater in subjects with a
psychosis risk state who will later transit to psychosis as
compared to those who will not [36], supporting the exist-
ence of different psychosis high-risk endophenotypes [36].
Neuroimaging techniques have the potential to find true
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employed structural imaging methods and focused on re-
gions known to be affected in schizophrenic psychoses
such as hippocampus [42,43] or anterior cingulate cortex
[44]. Since then, a number of structural studies employing
whole-brain methods such as voxel-based morphometry
or region-of-interests methods have been published. As
compared to matched controls, high risk individuals show
significant alterations in regional gray matter volume re-
gardless of whether they subsequently develop the dis-
order [45]. These alterations are particularly evident in
prefrontal and temporolimbic areas [46]. The largest mul-
ticenter structural study conducted in UHR showed para-
hippocampal alterations predicting psychosis onset [45].
Aims
The primary aim of the current study is to test the effect
of a Prodromal Detection and Treatment program at the
health care systems level. The study will investigate; 1)
If the combination of information campaigns and detec-
tion teams modelled will help in identifying individuals
at high risk of developing psychosis early, and 2) If
a graded, multi-modal treatment program will reduce
rates of conversion compared to the rates seen in
follow-along assessments. The study will use the know-
ledge obtained and the treatment strategies developed
from recent experimental studies, and test them out on
the health care system level as a proof-of-concept study
that intervention in the prodromal phase may lead to a
reduction in the development of new cases. The end-
point or main outcome will be the rate of conversion
to psychosis. The study will be conducted within a
translational approach, comprising clinical and genetic
sub-projects as well as an FMRI sub study at Stavanger
University hospital, Norway done in close collabor-
ation with health regions in Southern Norway. The
aim of these sub-projects is to identify neurobiological
indicators of psychosis vulnerability.
Methods/Design
Overall design
The current study will use a health service design mod-
eled after the TIPS study, using the unique possibilities
of the Norwegian catchment area based treatment
systems. UHR patients from two areas (the catchment
areas of Stavanger and Fonna) will be recruited through
information campaigns and assessed by low-threshold
detection teams. Recruited individuals will, after giving
informed consent, receive structured follow-along by a
designated case manager, and receive a multi-modal
treatment package containing CBT, family work and
Omega-III fatty acids and with the possibility for
provision of antipsychotic medication only at imminent
risk of conversion. Study personnel blind to treatmentallocation will confirm this through a separate symptom-
atic evaluation.
Information campaigns and detection teams
Each Prodromal Detection and Treatment site will im-
plement a program building upon the combined experi-
ences from the TIPS study and previous prodromal
studies, consisting of Information Campaigns (IC) and
Low Threshold Detection Teams (DT) [2]. Prodromal
detection, like early psychosis detection, requires active
outreach and recruitment using information campaigns
and specialized detection teams. As demonstrated by the
TIPS project, both elements are likely to be critical [47].
Given that the threshold pathology in the prodrome is
likely to be more privately experienced and less publicly
apparent, the IC must be intense, persistent, pervasive,
and personal. The IC will use three concrete strategies:
A)Teaching the public about early signs of severe
mental illness, the importance of getting help early
and the existence of the low threshold DTs;
B) Provide targeted education programs for teachers
and General Practitioner’s (GPs) about prodromal
symptoms and the content and availability of the
PDT program;
C) Provide targeted education for clinicians in the
specialized mental health services to learn them to
recognize possible prodromal individuals.
Potential prodromal individuals in the PDT areas will
be referred to a DT by health care providers, educators,
or social service agencies or they can be self-referrals in
response to the IC. Potential subjects will undergo a
telephone and/or a face-to-face screen (Prodromal
Questionnaire, PQ-B) [48]. Those who screen positive
will be invited to an in-person eligibility and consent
evaluation based on the SIPS interview.
Prodromal treatment package
This will be modeled after practices tried out in the
TIPS study as well as practices shown to influence risk
of conversion in experimental studies and common to
existing prodromal centers. The patients will participate
in an individual 2 year follow-along containing the fol-
lowing elements:
1) One-to-one monitoring of clinical status, symptom levels
(prodromal and psychotic), risk profiles (suicidality,
dangerousness), instrumental and social functioning;
2) One-to-one case management to help deal with clinical,
familial, social and vocational crises, needs and deficits;
3) Omega-III fatty acids, in the form of 2g fish oils
containing approx. 1.5 g Etyl-Eicosapentaeonic Acid/
DHA with 80 mgs Vitamin E per day for 12 weeks;
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deal with social/cognitive distortions and deficits and
to maintain real world investment (based on the
EDIE II study) [49]. They will be offered 26 sessions of
CBT within a six months period. The CBT sessions
will be based on established cognitive models, be
collaborative, problem orientated, formulation driven,
normalizing, educational and time-limited with
Socratic questioning/ guided discovery;
5) Individuals that experience functional loss will in
addition receive single-family psycho-education to
inform patients and families about current problems,
how to understand and cope with them, especially
within the family [50,51];
6) Anti-anxiety agents and anti-depressants will be
available if the patient is so symptomatic that they
otherwise would be prescribed these agents by
their GPs;
7) Antipsychotic medication will be available if the
patient either enters the study with any SIPS positive
symptom score at the level of 5, or if any positive
prodromal symptom score(s) moves from a level of
3 or 4 to a 5. Use will be open labeled based on the
patients’ current symptom profile. The type and dose
of medication will be reviewed by an independent
clinical practice safety monitoring board.
Questionnaires and interviews
Participants will be screened with the Structured Inter-
view for DSM-IV (SCID) [52] /(Kiddie SADS for adoles-
cents who are 13–17 years old) and the SIPS at study
entrance. All participants will be followed with a symp-
tomatic assessment (SIPS) done monthly for the first six
months and then every three months for the last two
years. The participant will be evaluated by a designated
nevopsychological protocol at baseline, 12 and 24 month
follow-up and offered to participate in a fMRI substudy.
Assessors will not be part of the treatment teams.
Prodromal inclusion and exclusion criteria
Start of study inclusion is from March 1st 2012, ending
inclusion December 31st 2016.
1) The patient is listed in the national register and res-
iding in the catchment areas of: Stavanger and Fonna; 2)
Between 13 and 65 years; 3) Meet diagnostic criteria for
prodromal syndrome SIPS criteria [11]; 4) Does not
meet current or life-time criteria for any psychotic dis-
order; 5) The symptoms are not better accounted for by
an axis I, axis II or substance use disorder with the ex-
ception of schizotypal personality disorder (the presence
of any of these disorders in itself is not an automatic
reason for exclusion); 6) Does not use any antipsychotic
medication currently and have not used antipsychotic
medication (regardless of dosage) for more than fourweeks lifetime; 7) No known neurological or endocrine
disorders that may have caused the presenting psychotic
symptoms; 8) The patient is not mentally retarded with
an IQ below 70; 9) The patient must be able to under-
stand and speak Norwegian; 10) The patient must be
able to understand and sign an informed consent or
assent for minors’ document.
Power calculation
There are no previous studies giving any clear sugges-
tion of the number of high-risk individuals that can be
recruited from a well-defined catchment area sample like
the current, but previous studies in Melbourne indicate
that around 20% of first episode patients have been in
contact with the PACE clinic (McGorry, personal com-
munication). Studies up to now give a conservative esti-
mate of a 20% transition rate over the first two years for
a non-treated high-risk sample and subsequently a 10%
risk in the active treatment group. A power analysis has
shown that in order to give an achieved significant re-
duction of transition rates in the study population with
the proposed sample size for the two groups of a) 750
000 with predicted annually detection of 150 first-
episode psychosis (FEP) (Bergen and Østfold) and b)
440 000 with annually predicted reduction to 90 FEP
(Stavanger and Fonna) through prodromal detection
and intervention, the study will have power of 88.9% to
yield a statistically significant result.
The psychosis incidence study
The main outcome of the intervention will be the inci-
dence of psychotic disorders in the participating areas.
This will be assessed using the same research diagnostic
criteria; in all participating areas over all study years.
Incidence study inclusion criteria
1) The patient is listed in the national register and resid-
ing in the catchment areas of Stavanger, Fonna, Bergen,
and Østfold; 2) Between 13 and 65 years; 3) Meet diag-
nostic criteria in DSM-IV for first-episode schizophrenia,
schizophreniform disorder, schizoaffective disorder, delu-
sional disorder, brief psychotic disorder, affective psych-
oses (Bipolar I disorder, Bipolar II disorder with psychotic
symptoms, major depressive disorder with psychotic
symptoms) or psychotic disorders NOS; 4) The patient is
(or has recently been) active psychotic with symptoms of
delusions, hallucinations, disturbed thinking, unsuitable/
bizarre behaviour which cannot clearly be explained by or-
ganic reasons. The symptoms must have lasted the whole
day for several days or several times a week for several
weeks, not limited to some brief moments corresponding
to a score of at least 4 on one or more of the following
positive and negative symptom scale (PANSS) [53] symp-
toms: P1 (delusions), P3 hallucinations), P5 (grandiose
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content); 5) This is the first episode of the condition that
is being adequately treated. i.e. the patient has not re-
ceived antipsychotic treatment corresponding to 75% of a
defined daily dosage for more than eight weeks (shorter if
the symptoms remit); 6) There are no known neurological
or endocrine disorders that may have caused the present-
ing psychotic symptoms; 7) The patient is not mentally re-
tarded with an IQ below 70; 8) Able to understand and
speak Norwegian; 9) Able to understand and sign in-
formed consent/assent for minors’ document.
Assessments
The primary measure of the incidence study is psychotic
caseness as ascertained by SCID (Kiddie SADS for
adolescents who are 13–17 years old) assisted by the
PANSS interview.
Prodromal patient neuroimaging protocol
A fMRI protocol is set up for the prodromal study pro-
viding the possibility to study prodromal patients, and
normal controls. The MR imaging is performed with a
1.5 tesla scanner (450 Discovery; GE Medical Systems)
equipped with a standard head-and-spine (HNS) coil.
Structural images
A structural image is acquired after the functional im-
aging using a BRAVO sequence (GE Healthcare); a T1-
weight 3D IR-prepared spoiled gradient echo-sequence
with the following parameters: TR/TE/TI = 7.9 ms/3.1
ms/450 ms, FOV = 24 × 19.2 cm. Number of slices is
180 with a thickness of 1 mm. The in-plane sampling
matrix is set to 240 × 192 resulting in an iso-tropic reso-
lution of 1 mm. The total scan time is 6 min. 3 s.
Functional magnetic resonance imaging
Working memory task Participants undergoes fMRI
scanning while performing a numeric n-back WM task
as used in previous studies [54-56]. The task contains
two conditions: (1) in the “2-back” condition, partici-
pants are required to press a button when the number
they see equales the number seen two numbers before;
and (2) in the “0-back” condition, participants have to
respond with a button press each time they see the num-
ber zero. Numbers between 0 and 9 is displayed for 500
ms with an intertrial interval of 900 ms. Each block con-
sist of 22 stimuli containing three targets and is indi-
cated by an instruction cue displayed for 2 seconds
before each block. Stimulation blocks and resting pe-
riods alternates within the experiment with a total of six
2-back and six 0-back blocks. During resting periods,
volunteers are instructed to fixate on a cross in the cen-
ter of the screen.MRI is performed using gradient-echo echo-planar im-
aging (TR, 2600 ms; TE, 35 ms; flip angle, 90°; matrix,
64 × 64; voxel size, 2 × 4 × 5 mm). The combination of a
stimulus onset asynchrony of 1400 ms (500 ms stimulus
duration; 900 ms intertrial interval) and a TR of 2600 ms
resultes in 13 possible time points of stimulus presenta-
tion per TR. Across multiple stimulus presentations, this
yields an effective sampling rate of 5 Hz. Twenty-four
slices approximately parallel to the bicommissural plane
(anterior commissure–posterior commissure plane) are
collected, covering the whole brain. Twenty fMRI volumes
are acquired per block: 12 during stimulation (2-back or
0-back) and eight during the resting period. Blocks are
presented alternately three times in each of the two runs
(A B A B A B). A total of 252 volumes are collected.
Resting state task Subjects undergoes one 8 min scan
during which they performed a resting-state, low-level
baseline task (eyes open, visual fixation on a hair-cross-
centered in the screen). MRI is performed using gradient-
echo echo-planar imaging. The experiment consisted of a
single session during which 180 BOLD sensitive EPI vol-
umes are acquired with 25 axial slices (TR, 2500 ms; TE,
40 ms; flip angle, 90°, 5 mm slice thickness, no interslice
gap, matrix, 64 × 64; field of view: 240 × 200 mm2; voxel
size, 2 × 4 × 5 mm).
Dichotic listening task The paradigm consist of di-
chotic presentations of pairs of consonant–vowel (CV-)
syllables, i.e. two different syllables were simultaneously
presented, one to the left and one to the right ear
[57-59]. The syllable pairs is formed combining the six
syllables /ba/, /da/, /ga/, /pa/, /ta/, and /ka/ to all pos-
sible 30 pairs of unidentical syllables (e.g., /ba/ presented
to the left and /da/ presented to the right ear), i.e. also
including the reversed pairing (e.g., /da/ presented to the
left and /ba/ presented to the right ear). The syllables is
spoken by an adult Norwegian male voice with constant
intensity and intonation. The syllables in each pair are
temporally aligned to achieve simultaneous onset of the
initial consonants. The stimulus duration varies between
400 and 450 ms. The fMRI paradigm is presented as
block-design, including in total nine task blocks (inter-
leaved with a rest block) each containing ten syllable pair
presentations, amounting to in total 90 stimulus presen-
tations (equivalent to three times the total set of syllable
pairs). The first three blocks are presented with no spe-
cific attention instruction (NF), i.e. the subjects are
instructed to report the syllable which they heard best in
each trial. For the remaining six blocks the subjects are
asked to focus their attention to and report the left- (FL)
or the right-ear stimulus (FR), respectively. In all three
conditions, the instruction is to accurately report the syl-
lable (with no emphasis on response speed). The order
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randomised (order: ABBABA). This approach of starting
with the NF blocks, followed by the forced attention
blocks, is chosen to avoid “carryover” effects that might
result from presenting the forced attention conditions
first, since individuals might not be able to “not attend”
once instructed to attend to a particular side in auditory
space [60].
Before entering the MR scanner all subjects conducts
five practice trials (with the NF instruction) in order to
familiarize them with stimulus material and procedure.
Here, the subjects are also informed that in addition to
the just-practiced NF condition, two other conditions
will be presented, during which they will be asked to se-
lectively attend to one ear and only report the syllable
presented to this ear. Inside the scanner, instructions are
given via head-coil mounted goggles (Nordic Neuro Lab,
Bergen, Norway). Each instruction consists of a brief
sentence asking the subject to report the syllable which
is heard the best (NF), in the right ear (FR), in the left
ear (FL), or to relax (rest block). The instruction screen
is after 2500 ms replaced by a fixation cross on which
the subjects are instructed to focus their eyes. Through-
out all blocks, the inter-stimulus interval is 5500 ms.
Stimulus administration is controlled by E-Prime software
(Psychology Software Tools Inc., Pittsburgh, PA) and the
dichotic stimuli is presented using MR-compatible head-
phones (Nordic Neuro Lab, Bergen, Norway). The subjects’
response were given orally and is recorded with an mp3-
recorder connected to an MR-compatible microphone.
The resulting recordings will be analyzed and coded.
The percentage of correctly reported syllables will be de-
termined separately for the left-ear (LE) and the right-
ear (RE) stimuli in each of the three conditions. In order
to quantify the effect of attention we will calculate two
“attentional gain scores” [61]: (1) the increase in the
number of correct right-ear report from NF to FR (de-
fined as: REgain = FR_RE −NF_RE); and (2) the increase
of correct left-ear report from NF to FL (LEgain =
FL_LE −NF_LE).
Functional imaging is performed using a sparse-
sampling echo-planar imaging (EPI) sequence, i.e. EPI
volumes are acquired with a repetition time of 5.5 s and
an acquisition time of 1.5 s, leaving a silent gap of 4 s,
during which the dichotic stimuli are presented and the
subjects’ verbal response is given [62]. The experiment
consists of a single session during which 180 BOLD sen-
sitive EPI volumes were acquired with 25 axial slices
(field of view 240 × 75 mm2; scan matrix 64 × 64; 3 mm
slice thickness, no interslice gap; voxel size 1 × 4 × 3
mm, echo time of 35 ms), covering most of the cere-
brum. The experimental stimulation follows a block de-
sign with nine blocks, three per condition (see above).
Each block contains ten volume acquisitions, with onetrial per silent gap and lasting for 55 s. Each block of
the nine experimental blocks is followed by a rest-block
(10 scans, 55 s).
Ethical approval
The study is approved by the National Committee for
Medical and Health Research Ethics (2009/949). Partici-
pation in the prodromal study will be based on written
informed consent. All data from the Patient Record
System for patients registered in the incidence study will
be depersonalized by health professionals who already
have access to the information before it is delivered to
the researchers.
Discussion
Evidence has been accumulating that it may be possible
to achieve prevention in psychotic disorders. Solid evi-
dence has come forward from the TIPS study for tertiary
and secondary prevention, providing proof of concept
that prevention in psychosis is possible and might be ex-
tended to the disorder itself. Direct but preliminary evi-
dence for primary prevention has been generated by
clinical trials in Australia, Europe and the US. If we can
identify people about to become psychotic with high ac-
curacy, we can track them to understand more about
how psychosis unfolds. Appropriate intervention at this
stage could also prevent or delay the onset of psychosis
and/or subsequent deterioration, i.e., social and instru-
mental disability, suicide, aggressive behavior, affective-
and cognitive deficits. However, there are still major
methodologically and practical challenges that need to
be solved. The health services need to be able to identify
and recruit persons who meet the current criteria which
might be difficult because individuals in the high risk
group don’t necessarily seek guidance actively. Other
challenges concern the sensitivity and specificity of the
current UHR criteria, which in turn reflects the hetero-
geneity of a psychosis high-risk state as well as the het-
erogeneity of the traditional mental disorders.
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